Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)
- Sponsor
- Ludwig-Maximilians - University of Munich
- Study ID
- NCT07586150
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Bipolar Disorder (BD)
- Depression / Major Depressive Disorder
- Schizophrenia
- Severe Mental Illness
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 65 Years
- Healthy Volunteers
- Not accepted
Interventions
- Semaglutide (SEMA) — DRUGOnce-weekly subcutaneous semaglutide for eligible participants with overweight or obesity and metabolic risk, titrated according to protocol up to 2.4 mg/week as tolerated, followed by tapering after Month 6.
- Exercise module — BEHAVIORALPersonalized moderate-intensity exercise intervention with supervised sessions during the structured phase and supported maintenance, targeting at least 150 minutes of moderate physical activity per week.
- Anti-inflammatory diet module — BEHAVIORALStructured anti-inflammatory dietary intervention based on the Brain Anti-Inflammatory Nutrition (BrAIN) diet, supported by coaching, recipes, and digital materials.
- Sleep intervention module — BEHAVIORALAdapted cognitive behavioral therapy for insomnia (SLEEPexpert) including a structured introduction and supported self-management.
- Social prescribing module — BEHAVIORALStructured intervention to increase social participation, community engagement, and behavioral activation.
- Closed-loop transcranial alternating current stimulation (CL-tACS) — DEVICEOptional adjunctive bifrontal closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms.
- Structured lifestyle psychoeducation — BEHAVIORALControl intervention consisting of psychoeducation and counseling on lifestyle domains with self-guided continuation.
- Sham CL-tACS — DEVICESham closed-loop transcranial alternating current stimulation in the control arm for eligible participants with prominent depressive symptoms.
Study Details
This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar disorder, or major depressive disorder. Participants will be randomized to either a modular individualized intervention program or a structured psychoeducation control condition. The individualized intervention may include physical exercise, an anti-inflammatory diet, sleep intervention, social prescribing, semaglutide for eligible participants with overweight or obesity, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. The primary outcome is change in the SF-36 Mental Component Summary score from baseline to Month 3.
Key Dates
- Start date
- Oct 31, 2028
- Status verified
- May 2026
- Primary completion
- Jul 31, 2030
- Completion
- Dec 31, 2030
Study Design
- Enrollment
- 140 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Personalized pharmaco-lifestyle interventionParticipants receive one or more individualized intervention modules selected according to predefined eligibility criteria, digital guidance, and shared decision-making. Modules may include exercise, anti-inflammatory diet, sleep intervention, social prescribing, semaglutide, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. Weekly guided support is provided through Month 3, followed by self-directed continuation with digital support through Month 6.
- Active Comparator: Structured lifestyle psychoeducation controlParticipants receive structured psychoeducation and counseling on exercise, diet, sleep, and social contact approximately every four weeks through Month 3, followed by self-guided continuation through Month 6. Participants with prominent depressive symptoms may receive sham closed-loop transcranial alternating current stimulation.
Primary Outcome Measure
Change in Short Form 36 Health Survey (SF-36) Mental Component Summary (MCS) score [ Time Frame: Baseline to Month 3 ]
Central Contacts
- Peter Falkai, MD+49 89 4400 - 55501
Related Studies
- Zyprexa® Relprevv™ Patient Care ProgramEnrolling By Invitation · Eli Lilly and Company · Blue Bell, Pennsylvania
- Database Registry for Neural Network Biomarkers in PsychosisRecruiting · University of Texas Southwestern Medical Center · Dallas, Texas
- Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) ScanningRecruiting · Yale University · New Haven, Connecticut
- Neuronal Effects of Exercise in SchizophreniaRecruiting · University of Colorado, Denver · Aurora, Colorado